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Glioblastoma (GBM) is the most common primary brain 
tumour with dismal prognosis. Tumours exhibit inherent 
resistance to radiation and chemotherapy which has been 
attributed to a subpopulation of cancer cells termed ‘GBM 
stem-like cells’ (GSC) characterised by multipotentiality and 
potent tumorigenic capacity. The use of established cancer 
cell lines in simplified two-dimensional (2D) in vitro cultures 
might explain the observed discrepancy between pre-clinical 
and clinical responses to cytotoxic treatments. We developed 
a customised, 3D GSC culture system using a polystyrene 
scaffold (Alvetex®) that recapitulates key histological 
features of GBM including high cellularity and sparse 
extracellular matrix (ECM) and compared it to conventional 
2D GSC cultures. 2D and 3D cultures of three different 
primary GSC lines exhibited similar radiation sensitivities as 
measured by clonogenic survival. Previous studies have 
demonstrated radiopotentiating efficacy of the epidermal 
growth factor receptor (EGFR) inhibitor erlotinib against GBM 
cell lines in 2D cultures; however it failed in GBM clinical 
trials. Thus we evaluated the radiation modifying effects of 
erlotinib on 2D and 3D GSC cultures. Erlotinib enhanced 
radiosensitivity of 2D GSC cultures but had no effect on 
radiation responses of 3D GSC or in neurosphere formation 
assays, where cells grow in 3D conditions devoid of a scaffold 
or extrinsic ECM. We next examined VEGF inhibition, since 
anti-VEGF therapy in combination with standard radio-
chemotherapy increases progression-free survival of GBM 
patients. VEGF deprivation was associated with significant 
radiosensitisation of 3D GSC cultures but had no effect on 2D 
GSC. Erlotinib treatment of VEGF-deprived 3D cultures 
increased radiation resistance of 3D cells to the same extent 
as VEGF addition, indicating epistasis. EGFR has been shown 
to regulate repair of radiation-induced double-strand breaks 
by activating the non-homologous end-joining (NHEJ) repair 
protein DNA-PKcs. A correlation between radiosensitivity, 
increased gH2AX foci and phospho-DNA-PK nuclear foci after 
radiation treatment was observed. In contrast, increased 
numbers of foci of the homologous recombination (HR) repair 
protein Rad51 were observed in radioresistant populations. 
Our results show that in the 3D model, VEGF signalling is 
required for optimal NHEJ activation with fast kinetics. This 
effect allows access to HR repair proteins at the remaining 
unrepaired DSBs at later time points, facilitating their repair 
and conferring radiation protection. Detailed analysis of the 
signalling pathways involved in the radiation resistance 
conferred by VEGF and EGFR signalling in the 3D and 2D 
models respectively demonstrated a radioprotective role of 
the downstream signaling molecule Akt. Specific inhibition of 
Akt using the small molecule inhibitor MK-2206 increased 
radiation sensitivity to the same extent as VEGF deprivation 
in 3D cells or erlotinib treatment in 2D cells, and no 
additivity was observed when these agents were combined. 
Our results for erlotinib treatment and VEGF deprivation in 
the 3D model recapitulate data from clinical trials, and 
suggest novel therapeutic targets for GBM. The 3D-specific 
effects of this panel of molecularly targeted agents strongly 
support the clinical relevance of this 3D model and its 
potential value in preclinical studies. 
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Tumour-specific immunity occurs in cancer patients but has 
insufficient potential to control or eliminate the tumour. 
Strengthening this response through immunotherapy may lead 
to a durable, systemic response that may also control 
(development of)metastases. 
Radiotherapy - a standard treatment for cancer - acts 
through induction of DNA damage in cancer cells. Although 
this treatment was thought to e immuno suppressive for a 
long time, recent data show that radiotherapy can support 
tumour-specific immunity. In fact, there is accumulating 
evidence that immune stimulation is an integral part of this 
therapy. 
Using preclinical cancer models we showed that the efficacy 
of radiotherapy crucially depends on CD8+ T cells and 
dendritic cells. Radiotherapy induces activation of tumour-
associated dendritic cells and accumulation of CD8+ T cells 
with protective effect or function within the tumour (1). 
These results prompted us to investigate whether similar 
changes occur in cancer patients and we compared the 
immune signature in paired biopsies that were obtained from 
sarcoma patients before and after radiotherapy. Most 
patients showed a significant upregulation of molecules and 
cell types associated with protective immunity and a 
concomitant downregulation of such characteristic for 
immune regulation/suppression. Importantly, those patients 
with the strongest changes towards protective immunity 
survived longer after radiotherapy (2, 3). 
Because it is largely unknown how radiotherapy supports 
tumour-specific immunity, we performed a semi-unbiased 
transcript analysis to identify pathways that change 
significantly upon radiotherapy. We found that radiotherapy 
induces transient and local activation of the classical and 
alternative pathway of complement in murine and human 
tumours, which results in local production of the 
anaphylatoxins C3a and C5a. Complement activation and 
subsequent production of anaphylatoxins happens 
downstream of radiotherapy-induced necrosis. The local 
production of C3a andC5a is crucial to clinical efficacy of 
radiotherapy and concomitant stimulation of tumour-specific 
immunity (4). 
Radiotherapy influences a plethora of pathways, which we 
are currently identifying, because we think that selectively 
promoting or inhibiting particular pathways in the context of 
radiotherapy may further promote tumour-specific immunity 
and increase the therapeutic efficacy.Because chronic 
inflammation is immunosuppressive whereas acute inflation 
supports immunity, we are comparing chronic radiotherapy 
(low-dose given in multiple fractions during weeks) with 
radiotherapy that includes radiation holidays (limited 
fractions of high-dose given with substantial breaks) with 
respect to efficacy and immune stimulation.  
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Summary: Whole Brain Radiotherapy (WBRT) may be 
administered with either prophylactic or palliative intent. I 
will discuss both these approaches and how they fit into our 
management of metastatic brain disease in the 21st century. 
 
Background: The use of Whole Brain Radiotherapy (WBRT) 
emerged as standard management for patients with brain 
metastases during the latter half of the 20th century (1,2,3). 
